Standout Papers
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group (2003)
- 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients (2016)
Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Phase II Study of an Outpatient Palliative Care Intervention in Patients With Metastatic Cancer
2008
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
1998
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
2010
Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence
2006
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
2010
Hallmarks of Cancer: The Next Generation
2011 Standout
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
2009
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Venous Thromboembolism and Cancer: Prevention of VTE
2001
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment
2006
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Health benefits of physical activity: the evidence
2006 Standout
The risk of venous thromboembolism is increased throughout the course of malignant glioma
2000
Symptom burden and performance status in a population‐based cohort of ambulatory cancer patients
2010
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
2009
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
2001
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
1996
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study
2007
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial
2008
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials
2007
Nausea and Vomiting Remain a Significant Clinical Problem
2000
Prognosis of Cancers Associated with Venous Thromboembolism
2000 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
New antiemetic drugs
2006
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
1997
Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
1999
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30
1996
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting
2000
Audit and feedback: effects on professional practice and health care outcomes
2006
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
2007
Cancer Metastasis: Building a Framework
2006 Standout
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1996 Standout
Patient expectation is a strong predictor of severe nausea after chemotherapy
2004
Palonosetron Hydrochloride Is an Effective and Safe Option to Prevent Chemotherapy-induced Nausea and Vomiting in Children
2008
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
2006
Delayed emesis: incidence, pattern, prognostic factors and optimal treatment
2002
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy
1997
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Randomized, placebo‐controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting
2008
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome
1995 Standout
Depression as a predictor of disease progression and mortality in cancer patients
2009
Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting
2012
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Use of Antiemetic Agents in Acute Gastroenteritis
2008
Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin
2005
Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer
1997
The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers
2004
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
2008
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
2000 Standout
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Platelet Activation and Atherothrombosis
2007 Standout
Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3).
1998
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
1996
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
2005
Treatment of nausea and vomiting: Gaps in our knowledge
2006
Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation.
1995
Drug Treatment of Chemotherapy-Induced Delayed Emesis
1996
The benefits of being present: Mindfulness and its role in psychological well-being.
2003 Standout
The microenvironment of the tumour–host interface
2001 StandoutNature
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
2009
Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways
2017 StandoutNobel
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.
1994
Fatigue in ovarian carcinoma patients
2003
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Prevention of Venous Thromboembolism
2004 Standout
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
2012
Response criteria for phase II studies of supratentorial malignant glioma.
1990 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinoma
2004
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
2003
Cancer treatment and survivorship statistics, 2012
2012 Standout
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
1997 Standout
Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study
1997
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
2001
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
2001 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Subjective wellbeing, health, and ageing
2014 StandoutNobel
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update
2004
Matrix metalloproteinase inhibition: A review of anti-tumour activity
1995
Head and Neck Cancer
1993 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Cancer and venous thromboembolism
1996
Rotavirus Stimulates Release of Serotonin (5-HT) from Human Enterochromaffin Cells and Activates Brain Structures Involved in Nausea and Vomiting
2011
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study
2008
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study
2005
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Prevention of Venous Thromboembolism
2008 Standout
Chemotherapy-Related Change in Cognitive Function: A Conceptual Model
2007
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 Standout
Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy
2006
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
1995
How common is fatigue in disease-free breast cancer survivors? A systematic review of the literature
2007
Cancer‐related fatigue
2003
Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study
2005
Measuring Response in Solid Tumors: Unidimensional Versus Bidimensional Measurement
1999
Audit and feedback: effects on professional practice and health care outcomes
2003
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
2012
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
2003
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Hemorrhagic Complications of Anticoagulant Treatment
2001 Standout
Prevention of Venous Thromboembolism
1998
Hemorrhagic Complications of Anticoagulant Treatment
2004
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
2009
Venous thromboembolism and survival in patients with high-grade glioma
2007
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Management of Anticoagulation before and after Elective Surgery
1997
Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist
2003
Symptom Frequency and Severity in Patients with Metastatic or Locally Recurrent Lung Cancer: A Prospective Study Using the Lung Cancer Symptom Scale in a Community Hospital
2001
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
2001
Audit and feedback: effects on professional practice and healthcare outcomes
2012 Standout
Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
2009
Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin)
1996
Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
1985
Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone
1999
Minidose Warfarin and Failure to Prevent Deep Vein Thrombosis After Joint Replacement Surgery Despite Inhibiting the Postoperative Rise in Plasminogen Activator Inhibitor Activity
1995
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
2006
Platelets and cancer
2002
Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications
2005
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
2016
Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study
2012
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
2005
Clinical Trials on Antiphospholipid Syndrome: What is Being Done and What is Needed?
1994
State-of the-Art Review : Prevention of Thrombosis in Gynecologic Malignancy
1998
Venous Thromboembolism and Cancer: Risks and Outcomes
2003
Integrative Nonpharmacologic Behavioral Interventions for the Management of Cancer-Related Fatigue
2007
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy
2009
Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial
2005
Self-Reported Quality of Life of Individual Cancer Patients: Concordance of Results With Disease Course and Medical Records
2001
Effects of Fixed Low-Dose Warfarin, Aspirin-Warfarin Combination Therapy, and Dose-Adjusted Warfarin on Thrombogenesis in Chronic Atrial Fibrillation
2000
Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment
2006
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
Benefit of Temozolomide Compared to Procarbazine in Treatment of Glioblastoma Multiforme at First Relapse: Effect on Neurological Functioning, Performance Status, and Health Related Quality of Life
2005
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
2006
Prospective, Longitudinal Quality‐of‐Life Study of Patients With Head and Neck Cancer: A Feasibility Study Including the EORTC QLQ‐C30
1997
Health-Related Quality of Life in Patients Treated With Temozolomide Versus Procarbazine for Recurrent Glioblastoma Multiforme
2000
Criteria of tumor response used in clinical trials of chemotherapy.
1985
Local opinion leaders: effects on professional practice and health care outcomes
2011
Quality of Life in Head and Neck Cancer Patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35
1999 Standout
Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence
2000
Low-Molecular-Weight Heparins
1997 Standout
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
5-Hydroxytryptamine-3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (SC19)
2006
Cisplatinum and Bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial
1985
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
2004
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
2011
Prevention of Venous Thromboembolism
1995
Quality of Life Supersedes the Classic Prognosticators for Long-Term Survival in Locally Advanced Non–Small-Cell Lung Cancer: An Analysis of RTOG 9801
2009
Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain
2011 StandoutNobel
Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone
2001
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
2005
Cognitive Impairment Associated With Chemotherapy for Cancer: Report of a Workshop
2004
Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
2005
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Social Relationships and Health.
2004 Standout
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis
2002
Dexamethasone, Granisetron, or Both for the Prevention of Nausea and Vomiting during Chemotherapy for Cancer
1995
Thromboembolism in Hospitalized Neutropenic Cancer Patients
2006
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
2012
Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs
2010 Standout
Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?
2003
Works of David Warr being referenced
A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis
1993
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.
1998
Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
1994
Consensus proposal for 5HT 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy
1998
Delayed emesis: moderately emetogenic chemotherapy
2004
Acute emesis: moderately emetogenic chemotherapy
2004
The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.
1991
Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study
2001
Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil
1993
The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials
2005
Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines
2004
Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy
2005
Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy
1995
Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
1994
Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
1990
A Phase 2 study of perifosine in advanced or metastatic breast cancer
2007
Antiemetics in children receiving chemotherapy
2004
Superiority of Granisetron to Dexamethasone Plus Prochlorperazine in the Prevention of Chemotherapy-Induced Emesis
1991
A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer
1993
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting
1994
Small-cell carcinoma of the lung: derivation of a prognostic staging system.
1991
Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer
1994
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
1997
Age-Related Patterns in Adaptation to Cancer Pain: A Mixed-Method Study
2009
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
1998
Effect of postchemotherapy nausea and vomiting on health-related quality of life
1997
Quality of Life Studies in Chemotherapy-Induced Emesis
1996
Standard treatment of chemotherapy-induced emesis
1997
A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer
1998
A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron
1995
Evidence-based recommendations for the use of antiemetics in radiotherapy
2005
Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital
2006
Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy
2005
Dexamethasone (DEX) improves the efficacy of granisetron (GRAN) in the first 24 hours following high dose cisplatin (HDCP) chemotherapy
1993
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
1998
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
1984
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
2003 Standout
Antiemetics in children receiving chemotherapy
2005
Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer
2003